Oshagbemi OA, et al. - Authors, herein, assessed the risk of fractures with intermittent exposure to high-dose glucocorticoids (GC) in patients with chronic obstructive pulmonary disease (COPD) and the effect of proxies of disease severity. They noted that in patients with COPD intermittent high-dose GCs was not related to an increased risk of any, osteoporotic, hip or clinically symptomatic vertebral fractures. However, current GC use was seen to be related to an elevated risk of hip and clinically symptomatic vertebral fractures. Hence, in patients with COPD receiving intermittent dose of GCs, emphasis on prophylactic treatment of fractures may not be essential. On the contrary, this ought to be considered for high-dose long-term users with advanced COPD disease stage, postmenopausal women, and men over 40 years.